Brendon Neuen's Publications

About Brendon Neuen's Publications

Program Lead, Renal and Metabolic
  • Nephrologist and Director, Kidney Trials, Royal North Shore Hospital
  • Clinical Associate Professor, University of Sydney
  • Conjoint Associate Professor, UNSW Sydney
  • Ph.D. ,
  • MBBS(Hons),
  • MSc(Oxon),
  • FRACP,
  • FASN

  • Risk-directed management of chronic kidney disease

    Nature Reviews Nephrology Date published:

  • Canagliflozin reduces oral loop diuretic intensification in patients with type 2 diabetes: A participant-level pooled analysis of the CANVAS and CREDENCE trials

    European Journal of Heart Failure Date published:

  • Effects of anti-inflammatory agents on clinical outcomes in people with chronic kidney disease: a systematic review and meta-analysis of randomized control trials

    Clinical Kidney Journal Date published:

  • Cardiovascular, kidney and safety outcomes with canagliflozin in older adults: A combined analysis from the CANVAS Program and CREDENCE trial

    Diabetes, Obesity and Metabolism Date published:

  • Natriuretic Peptides, Kidney Function, and Clinical Outcomes in Heart Failure With Preserved Ejection Fraction

    JACC: Heart Failure Date published:

  • Angiotensin Receptor Neprilysin Inhibition and Cardiovascular Outcomes Across the Kidney Function Spectrum

    JACC: Heart Failure Date published:

  • Combination therapy as a new standard of care in diabetic and non-diabetic chronic kidney disease

    Nephrology Dialysis Transplantation Date published:

  • The association between sodium-glucose cotransporter 2 inhibitors and contrast-associated acute kidney injury in patients with type 2 diabetes undergoing angiography: a propensity-matched study

    European Journal of Medical Research Date published:

  • Therapeutic Effects of Heart Failure Medical Therapies on Standardized Kidney Outcomes: Comprehensive Individual Participant-Level Analysis of 6 Randomized Clinical Trials

    Circulation Date published:

  • The potential for reducing greenhouse gas emissions through disease prevention: a secondary analysis of data from the CREDENCE trial

    The Lancet Planetary Health Date published:

  • Cardiovascular, Kidney, and Safety Outcomes With GLP-1 Receptor Agonists Alone and in Combination With SGLT2 Inhibitors in Type 2 Diabetes: A Systematic Review and Meta-Analysis

    Circulation Date published:

  • Discontinuation of SGLT2i in people with type 2 diabetes following hospitalisation for heart failure: A cause for concern?

    Diabetes, Obesity and Metabolism Date published:

  • Contemporary epidemiology of hospitalised heart failure with reduced versus preserved ejection fraction in England: a retrospective, cohort study of whole-population electronic health records

    The Lancet Public Health Date published:

  • Bidirectional Relationship Between Kidney Disease Progression and Cardiovascular Events in Type 2 Diabetes

    Journal of the American College of Cardiology Date published:

  • Why Has it Been Challenging to Modify Kidney Disease Progression in Patients With Heart Failure?

    Journal of the American College of Cardiology Date published:

  • Sacubitril/Valsartan in Patients With Heart Failure and Deterioration in eGFR to <30 mL/min/1.73 m2

    JACC: Heart Failure Date published: